Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.264 · RIGHT
Ensemble
0.132 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.054
2,788 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized...
Read full article at Montreal Gazette ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1
Jun 3, 2026